Pablo Lee

A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy

Kiyotaka Yoh, Yukio Hosomi, Kazuo Kasahara et al. · Lung Cancer · 2016 · 112 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Teaching Synthetic Biology, Bioinformatics and Engineering to Undergraduates: The Interdisciplinary Build-a-Genome Course

Jessica S. Dymond, Lisa Z. Scheifele, Sarah M. Richardson et al. · Genetics · 2008 · 69 citations · Full text

Engineering, Bioinformatics, Biological Engineering +14

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

D. Ross Camidge, Eamon M. Berge, Robert C. Doebele et al. · Journal of Thoracic Oncology · 2014 · 51 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

Martin Reck, Luis Paz‐Ares, Paolo Bidoli et al. · Lung Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy

M. Pérol, Tudor–Eliade Ciuleanu, Óscar Arrieta et al. · Lung Cancer · 2016 · 45 citations

Medicine, Oncology, Pharmacology +15